AU2009268289B2 - Von Willebrand Factor or Factor VIII and von Willebrand Factor for the treatment of coagulopathy induced by inhibitors of thrombocytes - Google Patents

Von Willebrand Factor or Factor VIII and von Willebrand Factor for the treatment of coagulopathy induced by inhibitors of thrombocytes Download PDF

Info

Publication number
AU2009268289B2
AU2009268289B2 AU2009268289A AU2009268289A AU2009268289B2 AU 2009268289 B2 AU2009268289 B2 AU 2009268289B2 AU 2009268289 A AU2009268289 A AU 2009268289A AU 2009268289 A AU2009268289 A AU 2009268289A AU 2009268289 B2 AU2009268289 B2 AU 2009268289B2
Authority
AU
Australia
Prior art keywords
vwf
administered
fviii
factor
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009268289A
Other languages
English (en)
Other versions
AU2009268289A1 (en
Inventor
Gerhard Dickneite
Thorsten Haas
Henrique Lessa
Ingo Pragst
Stefan Zeitler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009268289(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of AU2009268289A1 publication Critical patent/AU2009268289A1/en
Application granted granted Critical
Publication of AU2009268289B2 publication Critical patent/AU2009268289B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009268289A 2008-07-10 2009-07-10 Von Willebrand Factor or Factor VIII and von Willebrand Factor for the treatment of coagulopathy induced by inhibitors of thrombocytes Active AU2009268289B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008032361A DE102008032361A1 (de) 2008-07-10 2008-07-10 Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
DE102008032361.6 2008-07-10
PCT/EP2009/005027 WO2010003687A1 (en) 2008-07-10 2009-07-10 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

Publications (2)

Publication Number Publication Date
AU2009268289A1 AU2009268289A1 (en) 2010-01-14
AU2009268289B2 true AU2009268289B2 (en) 2014-11-06

Family

ID=41171229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009268289A Active AU2009268289B2 (en) 2008-07-10 2009-07-10 Von Willebrand Factor or Factor VIII and von Willebrand Factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

Country Status (13)

Country Link
US (2) US8603979B2 (enExample)
EP (1) EP2310043B2 (enExample)
JP (1) JP5653916B2 (enExample)
KR (1) KR20110043654A (enExample)
CN (1) CN102088999A (enExample)
AU (1) AU2009268289B2 (enExample)
CA (1) CA2730290C (enExample)
DE (1) DE102008032361A1 (enExample)
DK (1) DK2310043T4 (enExample)
ES (1) ES2395855T5 (enExample)
PL (1) PL2310043T5 (enExample)
RU (1) RU2563236C2 (enExample)
WO (1) WO2010003687A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
JP5784907B2 (ja) 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 組換え型ｖｗｆ製剤
PL2300497T3 (pl) * 2008-06-24 2013-02-28 Octapharma Ag Sposób oczyszczania czynnika krzepnięcia VIII
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
AR074054A1 (es) 2008-10-21 2010-12-22 Baxter Healthcare Sa Formulaciones farmaceuticas de factor de von willebrand recombinante liofilizado
RS59670B1 (sr) 2012-01-12 2020-01-31 Bioverativ Therapeutics Inc Himerni polipeptidi faktora viii i njihove upotrebe
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
EP2662083A1 (en) * 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
CN103263663B (zh) * 2013-06-08 2016-05-04 兆科药业（合肥）有限公司 一种抗血小板溶栓素在制备治疗vwf缺陷型血管栓塞性疾病的药物中的应用
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5571784A (en) * 1994-10-20 1996-11-05 Behringwerke Aktiengesellschaft Use of VWF-containing concentrates as a therapy which is employed in combination with antithrombotic and fibrinolytic therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518482B2 (en) 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
WO2001047547A1 (en) † 1999-12-24 2001-07-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5571784A (en) * 1994-10-20 1996-11-05 Behringwerke Aktiengesellschaft Use of VWF-containing concentrates as a therapy which is employed in combination with antithrombotic and fibrinolytic therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Dickneite, G. et al. 1996 Platelets, vol. 7, pp. 283-290 *
Dickneite, G. et al. 1998 Thromb. Haemost. vol. 80, pp. 192-198 *
Elg, M. et al. 2001 Thrombosis Research, vol. 101, pp. 159-170 *
Plaimauer, B. et al. 2001 Semin. Thromb. Hemost. vol. 27, no. 4, pp. 395-403 *

Also Published As

Publication number Publication date
WO2010003687A1 (en) 2010-01-14
US20110112023A1 (en) 2011-05-12
EP2310043B1 (en) 2012-09-19
CA2730290C (en) 2017-02-07
AU2009268289A1 (en) 2010-01-14
PL2310043T5 (pl) 2024-02-05
ES2395855T5 (es) 2022-09-06
JP5653916B2 (ja) 2015-01-14
CA2730290A1 (en) 2010-01-14
ES2395855T3 (es) 2013-02-15
PL2310043T3 (pl) 2013-02-28
DE102008032361A1 (de) 2010-01-21
JP2011527301A (ja) 2011-10-27
RU2563236C2 (ru) 2015-09-20
US8603979B2 (en) 2013-12-10
RU2011104705A (ru) 2012-08-20
US20140128325A1 (en) 2014-05-08
EP2310043A1 (en) 2011-04-20
KR20110043654A (ko) 2011-04-27
EP2310043B2 (en) 2022-05-18
DK2310043T4 (da) 2022-06-20
CN102088999A (zh) 2011-06-08
US9095564B2 (en) 2015-08-04
DK2310043T3 (da) 2013-01-07

Similar Documents

Publication Publication Date Title
AU2009268289B2 (en) Von Willebrand Factor or Factor VIII and von Willebrand Factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
US20100298223A1 (en) Fibrinogen for treatment of bleeding in trauma and platelet disorders
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
Grobler et al. Reversal of vitamin K antagonists prior to urgent surgery
Lamont et al. Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantation
RU2290195C1 (ru) Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями
HU219595B (hu) Von Willebrand-faktort tartalmazó koncentrátumok alkalmazása trombózis elleni szerek és/vagy fibrinotikus szerek okozta vérzésnél antidotumként ható szer előállítására
Jung et al. Management strategies for perioperative anaemia in the severely burn-injured Jehovah’s Witness patients who decline a blood transfusion: A systematic review with illustrative case reports
Levy Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas
Bolliger et al. Fibrinogen—is it a universal haemostatic agent?
Franchini Thrombotic complications in von Willebrand disease
Levy et al. Anesthetic concerns for patients with coagulopathy
Galbusera et al. A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow
Haak et al. Use of Antithrombin Concentrate in Stable Diffuse Intravascular Coagulation: A Case Report
Khamis et al. Combined administration of tranexamic acid and vitamin K proved perioperative blood loss reduction with cementless total hip replacement
Baud et al. Acquired von Willebrand syndrome in myeloproliferative disorder
Steib et al. HEMOSTATIC AGENTS: WHY, WHEN AND HOW?
Biss et al. Hematological and coagulation changes in sepsis
Huang PREOPERATIVE EVALUATION OF HEMOSTASIS Assessing the risk of perioperative bleeding is a fundamental compo-nent of the preoperative evaluation. PROCEDURAL BLEEDING RISK

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)